Key result
Bisoprolol significantly reduced all-cause mortality compared to placebo in patients with congestive heart failure at all tolerated dose levels, including low doses (RH 0.66; 95% CI 0.48-0.92).
Why the study?
Does bisoprolol reduce mortality in patients with congestive heart failure at all tolerated dose levels compared to placebo?
Population
2,647 patients with congestive heart failure (CHF) enrolled in the CIBIS II trial
Comparison
Bisoprolol at low dose, moderate dose, or high… vs Placebo at corresponding dose levels
Design
Cohort
Authors
Loading...
May support continuing bisoprolol at tolerated doses in HF; leaves open randomized confirmation of low-dose benefit.
RCT (n=2,647)
Does bisoprolol reduce mortality in patients with congestive heart failure at all tolerated dose levels compared to placebo?
Hazard Ratio: 0.66 (95% CI 0.48–0.92)
Bisoprolol reduces mortality in patients with congestive heart failure at all tolerated dose levels, suggesting that maintaining therapy at a tolerated dose is beneficial even if the target dose cannot be reached.
Tabassome Simon (2003) conducted an RCT in congestive heart failure (n=2,647). Bisoprolol vs. Placebo was evaluated on all-cause mortality (RH 0.66, 95% CI 0.48-0.92). Bisoprolol significantly reduced all-cause mortality compared to placebo in patients with congestive heart failure at all tolerated dose levels, including low doses (RH 0.66; 95% CI 0.48-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: